Literature DB >> 31632541

Synergistic effects of Lactobacillus rhamnosus culture supernatant and bone marrow mesenchymal stem cells on the development of alcoholic steatohepatitis in mice.

Chao Cai1, Da-Zhi Chen2, Li-Chao Ge1, Wen-Kai Chen1, Sha-Sha Ye1, Wei-Wei Ye1,3, Ying Tao1, Rui Wang1, Ji Li1, Zhuo Lin1, Xiao-Dong Wang1, Lan-Man Xu1,4,5, Yong-Ping Chen1.   

Abstract

The gut microbiota has been shown to play an important role in chronic liver disease. It has been found that both Lactobacillus rhamnosus and its culture supernatant have the potential to mitigate alcoholic steatohepatitis. However, the exact mechanism is still not fully understood. Bone marrow mesenchymal stem cells have immunosuppressive effects with few side effects. The synergistic effect between Lactobacillus rhamnosus culture supernatant and bone marrow mesenchymal stem cells (BMMSCs) deserves further observation. In this study, a mouse model of chronic alcoholic hepatitis was established by eight weeks of Lieber-DeCarli liquid diet feeding; and LGG-s, BMMSCs or a combination of the two were used to explore a new therapeutic method for alcoholic liver disease and to study the mechanism. The results showed that the combined LGG-s and BMMSC treatment might have a synergistic effect and could improve the symptoms of alcoholic hepatitis by regulating inflammation, autophagy and lymphocyte subsets through the PI3k/NF-kB and PI3K/mTOR pathways. With the treatment, the autophagy rate accelerated, and alcohol-induced natural killer B (NKB) cell and follicular helper T (TFH) cell numbers decreased. These findings suggest that the development of alcoholic hepatitis may occur via PI3K/NF-kB and PI3K/mTOR pathway overactivation as well as through NKB and TFH cell imbalances. Moreover, LGG-s and BMMSCs can regulate these factors and alleviate the disease. AJTR
Copyright © 2019.

Entities:  

Keywords:  Gut microbiota; alcoholic liver disease; bone marrow mesenchymal stem cells; mTOR; natural killer-like B cells

Year:  2019        PMID: 31632541      PMCID: PMC6789285     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  39 in total

1.  Budesonide in Autoimmune Hepatitis: The Right Drug at the Right Time for the Right Patient.

Authors:  Michael P Manns; Elmar Jaeckel; Richard Taubert
Journal:  Clin Gastroenterol Hepatol       Date:  2017-11-08       Impact factor: 11.382

2.  Sugary Kefir Strain Lactobacillus mali APS1 Ameliorated Hepatic Steatosis by Regulation of SIRT-1/Nrf-2 and Gut Microbiota in Rats.

Authors:  Yung-Tsung Chen; Yu-Chun Lin; Jin-Seng Lin; Ning-Sun Yang; Ming-Ju Chen
Journal:  Mol Nutr Food Res       Date:  2018-04-03       Impact factor: 5.914

3.  Mesenchymal stem cells ameliorate experimental autoimmune hepatitis by activation of the programmed death 1 pathway.

Authors:  Yi Chen; Si Chen; Li-Yuan Liu; Zhuo-Lin Zou; Yi-Jing Cai; Jin-Guo Wang; Bi Chen; Lan-Man Xu; Zhuo Lin; Xiao-Dong Wang; Yong-Ping Chen
Journal:  Immunol Lett       Date:  2014-10-28       Impact factor: 3.685

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

5.  Poxviruses Evade Cytosolic Sensing through Disruption of an mTORC1-mTORC2 Regulatory Circuit.

Authors:  Nathan Meade; Colleen Furey; Hua Li; Rita Verma; Qingqing Chai; Madeline G Rollins; Stephen DiGiuseppe; Mojgan H Naghavi; Derek Walsh
Journal:  Cell       Date:  2018-08-02       Impact factor: 41.582

6.  Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function, balances Treg and TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding.

Authors:  Rui-Cong Chen; Lan-Man Xu; Shan-Jie Du; Si-Si Huang; He Wu; Jia-Jia Dong; Jian-Rong Huang; Xiao-Dong Wang; Wen-Ke Feng; Yong-Ping Chen
Journal:  Toxicol Lett       Date:  2015-11-23       Impact factor: 4.372

7.  Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver.

Authors:  Yueli Tian; Jingting Ma; Wudong Wang; Lingjuan Zhang; Jia Xu; Kai Wang; Dongfu Li
Journal:  Mol Cell Biochem       Date:  2016-09-09       Impact factor: 3.396

Review 8.  Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease.

Authors:  Stefano Bibbò; Gianluca Ianiro; Maria Pina Dore; Claudia Simonelli; Estelle E Newton; Giovanni Cammarota
Journal:  Mediators Inflamm       Date:  2018-01-31       Impact factor: 4.711

Review 9.  Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease.

Authors:  Cong Liu; Jia-Zhi Liao; Pei-Yuan Li
Journal:  World J Gastroenterol       Date:  2017-03-21       Impact factor: 5.742

10.  Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis.

Authors:  Chien-Chao Chiu; Yung-Hao Ching; Yen-Peng Li; Ju-Yun Liu; Yen-Te Huang; Yi-Wen Huang; Sien-Sing Yang; Wen-Ching Huang; Hsiao-Li Chuang
Journal:  Nutrients       Date:  2017-11-06       Impact factor: 5.717

View more
  4 in total

Review 1.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

Review 2.  Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease.

Authors:  Yumeng Dong; Tiangang Xu; Guozheng Xiao; Ziyan Hu; Jingyu Chen
Journal:  Front Bioeng Biotechnol       Date:  2022-08-10

3.  Probiotic Lactobacilli ameliorate alcohol-induced hepatic damage via gut microbial alteration.

Authors:  Juseok Kim; Seong Woo Ahn; Joon Yong Kim; Tae Woong Whon; Seul Ki Lim; Byung Hee Ryu; Nam Soo Han; Hak-Jong Choi; Seong Woon Roh; Se Hee Lee
Journal:  Front Microbiol       Date:  2022-08-18       Impact factor: 6.064

Review 4.  Modulation of the PI3K/Akt/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response.

Authors:  Amir Hossein Mohseni; Vincenzo Casolaro; Luis G Bermúdez-Humarán; Hossein Keyvani; Sedigheh Taghinezhad-S
Journal:  Gut Microbes       Date:  2021 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.